ARS Pharmaceuticals, Inc. SPRY D&A

D&A at other companies

Aquestive Therapeutics, Inc.AQST

$136K-2.9%

ViatrisVTRS

$672.3M-0.9%

AMP

Amphastar PharmaceuticalsAMPH

$8.04M-3.7%

Neuropace, Inc.NPCE

$100K0.0%

Eton Pharmaceuticals, Inc.ETON

$1.13M+11.6%

FAQ

What is ARS Pharmaceuticals, Inc.'s D&A?

ARS Pharmaceuticals, Inc. (SPRY) reported D&A of $397K in Q1 2026.

How has ARS Pharmaceuticals, Inc.'s D&A changed year-over-year?

ARS Pharmaceuticals, Inc.'s D&A increased by 41.8% year-over-year, from $280K to $397K.

What is the long-term trend for ARS Pharmaceuticals, Inc.'s D&A?

Over 2 years (2023 to 2025), ARS Pharmaceuticals, Inc.'s D&A has grown at a 332.7% compound annual growth rate (CAGR), from $73K to $1.37M.

What does D&A mean?

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.